References
1. Ananthapanyasut W, Napan S, Rudolph EH, et al. Prevalence of atrial
fibrillation and its predictors in nondialysis patients with chronic
kidney disease. Clin J Am Soc Nephrol. 2010;5(2):173-181. doi:
10.2215/CJN.03170509.
2. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and
prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort
(CRIC). Am Heart J. 2010;159(6):1102-1107. doi:
10.1016/j.ahj.2010.03.027.
3. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney
disease with atrial fibrillation among adults in the United States:
REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.Circ Arrhythm Electrophysiol. 2011;4(1):26-32. doi:
10.1161/CIRCEP.110.957100.
4. Mitsuma W, Matsubara T, Hatada K, et al. Clinical characteristics of
hemodialysis patients with atrial fibrillation: The RAKUEN (Registry of
atrial fibrillation in chronic kidney disease under hemodialysis from
Niigata) study. J Cardiol. 2016;68(2):148-155. doi:
10.1016/j.jjcc.2015.08.023.
5. Bonde AN, Lip GY, Kamper AL, et al. Renal Function and the Risk of
Stroke and Bleeding in Patients With Atrial Fibrillation: An
Observational Cohort Study. Stroke. 2016;47(11):2707-2713. doi:
10.1161/strokeaha.116.014422.
6. Providência R, Marijon E, Boveda S, et al. Meta-analysis of the
influence of chronic kidney disease on the risk of thromboembolism among
patients with nonvalvular atrial fibrillation. Am J Cardiol.2014;114(4):646-653. doi: 10.1016/j.amjcard.2014.05.048.
7. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian
Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive
Guidelines for the Management of Atrial Fibrillation. Can J
Cardiol. 2020;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001.
8. Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral
Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation.J Am Coll Cardiol. 2017;69(20):2475-2484. doi:
10.1016/j.jacc.2017.03.540.
9. Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use
for stroke prevention in patients with newly diagnosed atrial
fibrillation: Results from GARFIELD-AF. Am Heart J.2019;213:35-46. doi: 10.1016/j.ahj.2019.03.013.
10. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on
Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.Circulation. 2016;134(1):24-36. doi:
10.1161/CIRCULATIONAHA.116.022361.
11. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and
systemic embolism with rivaroxaban compared with warfarin in patients
with non-valvular atrial fibrillation and moderate renal impairment.Eur Heart J. 2011;32(19):2387-2394. doi:
10.1093/eurheartj/ehr342.
12. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and Safety of
Dabigatran Compared With Warfarin in Relation to Baseline Renal Function
in Patients With Atrial Fibrillation. Circulation.2014;129(9):961-970. doi: 10.1161/CIRCULATIONAHA.113.003628.
13. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when
compared with warfarin in relation to renal function in patients with
atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart
J. 2012;33(22):2821-2830. doi: 10.1093/eurheartj/ehs274.
14. Chen H-Y, Ou S-H, Huang C-W, et al. Efficacy and Safety of Direct
Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease
and Dialysis Patients: A Systematic Review and Meta-Analysis. Clin
Drug Investig. 2021;41(4):341-351. doi: 10.1007/s40261-021-01016-7.
15. Di Lullo L, Tripepi G, Ronco C, et al. Safety and effectiveness of
rivaroxaban and warfarin in moderate-to-advanced CKD: real world data.J Nephrol. 2018;31(5):751-756. doi: 10.1007/s40620-018-0501-7.
16. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With
Apixaban Use in Patients With End-Stage Kidney Disease and Atrial
Fibrillation in the United States. Circulation.2018;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418.
17. Makani A, Saba S, Jain SK, et al. Safety and Efficacy of Direct Oral
Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease
and Atrial Fibrillation. Am J Cardiol. 2020;125(2):210-214. doi:
10.1016/j.amjcard.2019.10.033.
18. Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and Efficacy of
Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney
Disease. Ann Pharmacother. 2018;52(11):1078-1084. doi:
10.1177/1060028018781853.
19. Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban Versus Warfarin in
Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease
or Undergoing Hemodialysis. Am J Med. 2019;132(9):1078-1083. doi:
10.1016/j.amjmed.2019.04.013.
20. Loo SY, Coulombe J, Dell’Aniello S, Brophy JM, Suissa S, Renoux C.
Comparative effectiveness of novel oral anticoagulants in UK patients
with non-valvular atrial fibrillation and chronic kidney disease: a
matched cohort study. BMJ Open. 2018;8(1):e019638. doi:
10.1136/bmjopen-2017-019638.
21. Shin JI, Secora A, Alexander GC, et al. Risks and Benefits of Direct
Oral Anticoagulants across the Spectrum of GFR among Incident and
Prevalent Patients with Atrial Fibrillation. Clin J Am Soc
Nephrol. 2018;13(8):1144-1152. doi: 10.2215/CJN.13811217.
22. Liabeuf S, Laville SM, Bieber B, et al. Prescription of Direct Oral
Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or
Just Right? Kidney Int Rep. 2021;6(9):2496-2500. doi:
10.1016/j.ekir.2021.06.004.
23. Wetmore JB, Roetker NS, Yan H, Reyes JL, Herzog CA. Direct-Acting
Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic
Kidney Disease and Atrial Fibrillation. Stroke.2020;51(8):2364-2373. doi: 10.1161/STROKEAHA.120.028934.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
JP. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) Statement: Guidelines for reporting observational
studies. Int J Surg. 2014;12(12):1495-1499. doi:
10.1016/j.ijsu.2014.07.013.
25. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription
claims databases in pharmacoepidemiological research: the accuracy and
comprehensiveness of the prescription claims database in Quebec. J
Clin Epidemiol. 1995;48(8):999-1009. doi: 10.1016/0895-4356(94)00234-h.
26. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing
pharmacosurveillance with systematic collection of treatment indication
in electronic prescribing: a validation study in Canada. Drug
Saf. 2010;33(7):559-567. doi: 10.2165/11534580-000000000-00000.
27. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes
within medical services claims. J Clin Epidemiol.2004;57(2):131-141. doi: 10.1016/S0895-4356(03)00246-4.
28. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M. Using
medical services claims to assess injuries in the elderly: sensitivity
of diagnostic and procedure codes for injury ascertainment. J Clin
Epidemiol. 2000;53(2):183-194. doi: 10.1016/s0895-4356(99)00136-5.
29. Humphries KH, Jackevicius C, Gong Y, et al. Population rates of
hospitalization for atrial fibrillation/flutter in Canada. Can J
Cardiol. 2004;20(9):869-876. doi:
30. Perreault S, Shahabi P, Cote R, et al. Rationale, design, and
preliminary results of the Quebec Warfarin Cohort Study. Clin
Cardiol. 2018. doi: 10.1002/clc.22948.
31. Roy L, Zappitelli M, White-Guay B, Lafrance JP, Dorais M, Perreault
S. Agreement Between Administrative Database and Medical Chart Review
for the Prediction of Chronic Kidney Disease G category. Can J
Kidney Health Dis. 2020;7:2054358120959908. doi:
10.1177/2054358120959908.
32. Blais C LL, Hamel D, Brown K, Rinfret S, Cartier R, Giguère M,
Carroll C, Beauchamp C, Bogaty P. Évaluation des soins et surveillance
des maladies cardiovasculaires de santé publique du Québec et de
L’institut national d’excellence en santé et services sociaux.Gouvernement du Québec, Institut national de santé publique ,
Institut national d’excellence en santé et des services sociaux.2012:1-9. doi:
33. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding
accuracy of hospital discharge data for elderly survivors of myocardial
infarction. Can J Cardiol. 1999;15(11):1277-1282. doi:
34. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index
for use with ICD-9-CM administrative databases. J Clin Epidemiol.1992;45(6):613-619. doi: 10.1016/0895-4356(92)90133-8.
35. D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the
use of the Charlson comorbidity index with administrative data bases.J Clin Epidemiol. 1996;49(12):1429-1433. doi:
10.1016/s0895-4356(96)00271-5.
36. Crane SJ, Tung EE, Hanson GJ, Cha S, Chaudhry R, Takahashi PY. Use
of an electronic administrative database to identify older community
dwelling adults at high-risk for hospitalization or emergency department
visits: the elders risk assessment index. BMC Health Serv Res.2010;10:338. doi: 10.1186/1472-6963-10-338.
37. Fillion V, Sirois MJ, Gamache P, Guertin JR, Morin SN, Jean S.
Frailty and health services use among Quebec seniors with non-hip
fractures: a population-based study using adminsitrative databases.BMC Health Serv Res. 2019;19(1):70. doi:
10.1186/s12913-019-3865-z.
38. Austin PC, Stuart EA. Moving towards best practice when using
inverse probability of treatment weighting (IPTW) using the propensity
score to estimate causal treatment effects in observational studies.Stat Med. 2015;34(28):3661-3679. doi: 10.1002/sim.6607.
39. Allan V, Ramagopalan SV, Mardekian J, et al. Propensity score
matching and inverse probability of treatment weighting to address
confounding by indication in comparative effectiveness research of oral
anticoagulants. J Comp Eff Res. 2020;9(9):603-614. doi:
10.2217/cer-2020-0013.
40. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational
Research: Introducing the E-Value. Ann Intern Med.2017;167(4):268-274. doi: 10.7326/M16-2607.
41. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the
diagnosis and management of atrial fibrillation developed in
collaboration with the European Association for Cardio-Thoracic Surgery
(EACTS): The Task Force for the diagnosis and management of atrial
fibrillation of the European Society of Cardiology (ESC) Developed with
the special contribution of the European Heart Rhythm Association (EHRA)
of the ESC. Eur Heart J. 2021;42(5):373-498. doi:
10.1093/eurheartj/ehaa612.
42. Fu CM, Li LC, Lee YT, Wang SW, Hsu CN. Apixaban vs. Warfarin in
Atrial Fibrillation Patients With Chronic Kidney Disease. Front
Cardiovasc Med. 2021;8. doi: 10.3389/fcvm.2021.752468.
43. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in
Nonvalvular Atrial Fibrillation. N Engl J Med.2011;365(10):883-891. doi: 10.1056/NEJMoa1009638.
44. Yao X, Tangri N, Gersh BJ, et al. Renal Outcomes in Anticoagulated
Patients With Atrial Fibrillation. J Am Coll Cardiol.2017;70(21):2621-2632. doi: 10.1016/j.jacc.2017.09.1087.
45. Koos R, Mahnken AH, Muhlenbruch G, et al. Relation of oral
anticoagulation to cardiac valvular and coronary calcium assessed by
multislice spiral computed tomography. Am J Cardiol.2005;96(6):747-749. doi: 10.1016/j.amjcard.2005.05.014.
46. Shea MK, O’Donnell CJ, Hoffmann U, et al. Vitamin K supplementation
and progression of coronary artery calcium in older men and women.Am J Clin Nutr. 2009;89(6):1799-1807. doi:
10.3945/ajcn.2008.27338.
47. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral
anticoagulant treatment: friend or foe in cardiovascular disease?Blood. 2004;104(10):3231-3232. doi: 10.1182/blood-2004-04-1277.
48. Elango K, Javaid A, Khetarpal BK, et al. The Effects of Warfarin and
Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review.Cells. 2021;10(4):773. doi: 10.3390/cells10040773.